High Serum Carbohydrate Antigen (CA) 125 Level Is Associated With Poor Prognosis in Patients With Light-Chain Cardiac Amyloidosis

被引:3
|
作者
Li, Muzheng [1 ]
Wu, Zhijian [1 ]
Tudahun, Ilyas [1 ]
Liu, Na [1 ]
Lin, Qiuzhen [1 ]
Liu, Jiang [2 ]
Wang, Yingmin [1 ]
Chen, Mingxian [1 ]
Chen, Yaqin [1 ]
Qi, Nenghua [1 ]
Zhu, Qingyi [1 ]
Li, JunLi [3 ]
Li, Wei [4 ]
Tang, Jianjun [1 ]
Liu, Qiming [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha, Peoples R China
[4] Huaihua Hosp Tradit Chinese Med, Dept Cardiol, Huaihua, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
light-chain cardiac amyloidosis; CA; 125; prognostic predictor; overall survival; biomarkers; ADVANCED HEART-FAILURE; OVARIAN-CANCER; CA-125; LEVELS; NATRIURETIC PEPTIDE; STAGING SYSTEM; TUMOR-MARKERS; CA125; ELEVATION; CYTOKINES; PERITONEAL;
D O I
10.3389/fcvm.2021.692083
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims: Patients with light-chain cardiac amyloidosis (AL-CA) are characterized by high levels of serum carbohydrate antigen 125 (CA 125). However, studies have not explored the correlation between CA 125 and AL-CA. The aim of this study was to explore the clinical implications of an increase in CA 125 in patients with AL-CA. Methods and Results: A total of 95 patients diagnosed with AL-CA at the Second Xiangya Hospital were enrolled in this study. Out of the 95 patients with AL-CA, 57 (60%) patients had elevated serum CA 125 levels. The mean age was 59.7 +/- 10.0 years with 44 (77.2%) men in the high serum CA 125 group, and 61.8 +/- 9.6 years with 28 (73.7%) men in the normal group. Patients with high CA 125 showed higher rates of polyserositis (79.3% vs. 60.5%, p = 0.03), higher levels of hemoglobin (117.4 +/- 21.9 g/L vs. 106.08 +/- 25.1 g/L, p = 0.03), serum potassium (4.11 +/- 0.47 mmol/L vs. 3.97 +/- 0.40 mmol/L, p = 0.049), low-density lipoprotein-cholesterol (3.0 +/- 1.6 mmol/L vs. 2.3 +/- 1.10 mmol/L, p = 0.01), and cardiac troponin T (96.0 pg/mL vs. 91.9 pg/mL, p = 0.005). The median overall survival times for patients with high or normal serum CA 125 were 5 and 25 months, respectively (p = 0.045). Multivariate Cox hazard analysis showed that treatment without chemotherapy (HR 1.694, 95% CI 1.121-2.562, p = 0.012) and CA 125 (HR 1.002, 95% CI 1.000-1.004, p = 0.020) was correlated with high all-cause mortality. The time-dependent receiver operating characteristic (t-ROC) curve showed that the prediction accuracy of CA 125 was not inferior to that of cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and lactate dehydrogenase (LDH) based on the area under the curve. Conclusions: CA 125 is a novel prognostic predictor. High serum CA 125 values are correlated with low overall survival, and the accuracy of predicting prognosis is similar to that of traditional biomarkers in AL-CA.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain
    苗会蕾
    [J]. China Medical Abstracts (Internal Medicine), 2021, (03) : 186 - 186
  • [2] Reversing the poor prognosis of primary amyloid light-chain amyloidosis with cardiac involvement
    Jurczyszyn, Artur
    Rajtar-Salwa, Renata
    Sorysz, Danuta
    Zawislak, Barbara
    Suska, Anna
    Szostek, Marta
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2022, 132 (04):
  • [3] Association of cancer antigen 125 with long-term prognosis in light-chain cardiorenal amyloidosis
    Wu, Bifeng
    Shi, Jiaran
    Yu, Fangcong
    Wu, Yakui
    Tao, Xinran
    Xuan, Tianming
    Yang, Jinxiu
    Wang, Xingxiang
    [J]. CARDIORENAL MEDICINE, 2023, 13 (01) : 19 - 25
  • [4] Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis
    Chamarthi, B
    Dubrey, SW
    Cha, KR
    Skinner, M
    Falk, RH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (09): : 1242 - &
  • [5] Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels
    Qiu, Yu
    Zhang, Cong-li
    Shen, Kai-ni
    Su, Wei
    Feng, Jun
    Zhang, Lu
    Cao, Xin-xin
    Li, Jian
    [J]. ANNALS OF HEMATOLOGY, 2018, 97 (12) : 2465 - 2470
  • [6] Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels
    Yu Qiu
    Cong-li Zhang
    Kai-ni Shen
    Wei Su
    Jun Feng
    Lu Zhang
    Xin-xin Cao
    Jian Li
    [J]. Annals of Hematology, 2018, 97 : 2465 - 2470
  • [7] Echocardiographic phenotype and long-term prognosis in patients with light-chain cardiac amyloidosis
    Ntalianis, A.
    Tseliou, E.
    Repasos, E.
    Papadopoulou, E.
    Tselegkidi, M.
    Zografos, N.
    Ziogas, D.
    Koutsoukis, A.
    Maglaras, G.
    Stamoulopoulos, J.
    Koen, A.
    Dialoupi, I.
    Kastritis, E.
    Dimopoulos, M. A.
    Paraskevaidis, I.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 572 - 572
  • [8] Elevated carbohydrate antigen 125 (CA-125) predicts poor prognosis in cardiac resynchronization therapy of chronic heart failure patients
    Szeplaki, G.
    Perge, P.
    Boros, A.
    Nagy, V. K.
    Szilagyi, S. Z.
    Molnar, L.
    Tahin, T.
    Zima, E.
    Geller, L.
    Merkely, B.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 53 - 53
  • [9] High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score
    Prochazka, Vit
    Faber, Edgar
    Raida, Ludek
    Kapitanova, Zuzana
    Langova, Katerina
    Indrak, Karel
    Papajik, Tomas
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (01) : 58 - 64
  • [10] High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score
    Vít Procházka
    Edgar Faber
    Luděk Raida
    Zuzana Kapitáňová
    Kateřina Langová
    Karel Indrák
    Tomáš Papajík
    [J]. International Journal of Hematology, 2012, 96 : 58 - 64